Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 37

Sweetgreen steers itself toward public markets

Roc Nation-backed healthy restaurant chain Sweetgreen plans to float on the New York Stock Exchange having reportedly raised about $630m in funding.

Oct 26, 2021

JLL to buy Building Engines for $300m

The all-cash deal will provide an exit for Massachusetts Mutual Life when formally JLL takes over the property management platform developer.

Oct 26, 2021

23andMe to swallow Lemonaid for $400m

Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.

Oct 26, 2021

Daily Deal Round Up: October 25, 2021

Online insurance provider Justos raised $35.8m in a SoftBank-led series A round while social game studio GreenPark Sports closed a $31m series B that included Alameda Research.

Oct 25, 2021

Xilio Therapeutics tunes into $118m IPO

Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.

Oct 25, 2021

Q4 reaches the front of IPO queue

The market communicationns platform developer is going public today in an $81m initial public offering which will enable OpenText to exit.

Oct 25, 2021

Daily Deal Round Up: October 22, 2021

Automated driving software developer Jimu Intelligent raised over $31m from investors including UMC Capital and Avic Pingshan while Lockheed Martin took part in gyroscope technology developer Anello's $28m round.

Oct 22, 2021

Instacart pulls off $350m Caper AI purchase

Red Apple Group is exiting the smart trolley provider, which is being taken over by Instacart in a cash-and-stock deal.

Oct 22, 2021

Daily Deal Round Up: October 21, 2021

Battery swapping service Sun Mobility closed $50m in funding from Vitol while Sinopharm-backed drug developer Sinotau raised the same amount in a series D-plus round.

Oct 21, 2021

Saama cedes majority stake for $430m

Amgen, Merck & Co, Pfizer, Intermountain and McKesson were among the investors to jointly acquire a majority of the clinical trials software producer's shares.

Oct 21, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here